In a clinical study, FORTEO helped stimulate new bone with mineral properties consistent with younger bone age*10
FORTEO treatment increased the amount of newly formed bone matrix with lower, more heterogeneous mineral content (blue arrows), a property consistent with younger bone age.*
*Younger bone age is characterized by newly formed bone matrix with lower, more heterogeneous bone mineral content.
Analysis of mineralization at the tissue level shows that FORTEO promotes ongoing formation of new bone
FORTEO Select Safety Information
In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times the exposure in humans given a 20-mcg dose. The clinical relevance of the rat osteosarcoma finding to humans is unknown.
2. FORTEO Prescribing Information, 3. Riggs BL, Parfitt AM. J Bone Miner Res. 2005;20:177-184., 4. Raggatt LJ, Partridge NC. J Biol Chem. 2010;285:25103-25108., 5. Seeman E. Rheumatology (Oxford). 2008;47:iv2-iv8., 6. Dempster DW, et al. J Clin Endocrinol Metab. 2016;101:1353-1363., 7. Dempster DW, et al. J Bone Miner Res. 2016;31:1429-1439., 8. Dempster D, et al. J Clin Endocrinol Metab. 2012;97(8):2799-2808., 9. Data on file, Lilly Research Laboratories (FOR20161208A)., 10. Dempster DW, et al. J Bone Miner Res. 2016; 31(8):1527-1535.